Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247273 · ClinicalTrials.gov registry record · Phase 3
A Study of Monthly Risedronate for Osteoporosis
A Phase 3 study of Postmenopausal Osteoporosis, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,294
- Enrollment target
- 20
- Study locations
NCT00247273 is a Phase 3 study of Postmenopausal Osteoporosis that has completed, run by Warner Chilcott. The registered enrollment target is 1,294 participants, above the 478-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target (171% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00247273, a Phase 3 study of Postmenopausal Osteoporosis, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,294 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
Conditions Studied
Interventions
- DRUG risedronate
Study Locations (20)
Other
- Research Site - Capital Federal
- Research Site - Geelong
- Research Site - Heidelberg, Victoria
- Research Site - Saint Leonards
- Research Site - Brussels
- Research Site - Ghent
- Research Site - Leuven
- Research Site - Liège
- Research Site - Mont Godinne
- Research Site - Rio de Janeiro
- Research Site - São Paulo
- Research Site - Calgary
Colorado
- Research Site - Lakewood
Georgia
- Research Site - Gainesville
Maryland
- Research Site - Bethesda
Nebraska
- Research Site - Omaha
New York
- Research Site - West Haverstraw
Ohio
- Research Site - Cincinnati
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,294 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00247273
The ClinicalTrials.gov registry entry for NCT00247273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,294 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 478-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target (171% higher). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which risedronate is the first listed.
NCT00247273 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT00247273 about?
NCT00247273 is a clinical study titled "A Study of Monthly Risedronate for Osteoporosis". The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
What is the current status of trial NCT00247273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,294 participants. The study started on 2005-10. Estimated completion is 2008-04.
What conditions does trial NCT00247273 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT00247273?
The interventions under investigation include: risedronate (DRUG).
Who is sponsoring clinical trial NCT00247273?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00247273 being conducted?
This trial has 20 study locations across Colorado, Georgia, Maryland, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
-
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
COMPLETED · Phase 3
-
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
COMPLETED · Phase 3
-
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
COMPLETED · Phase 3
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.